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Abstract
Pheochromocytomas are rare tumours of the adrenal gland that secrete catecholamines. 
The classical presentation of these tumours consists of a clinical triad of headaches, pal‐
pitations and diaphoresis. This clinical presentation should not be confused with the 
potentially fatal presentation of pheochromocytoma crisis, which may include severe 
haemodynamic instability and collapse, multi‐organ failure, hyperthermia and encepha‐
lopathy. When patients present in profound shock, supportive care and treatment are 
initiated. Patients presenting with pheochromocytoma crisis have an underlying adrenal 
tumour, but the clinical manifestations of this life‐threatening condition can mimic other 
entities. Once diagnosis is made, previous anecdotal evidence has shown that pheochro‐
mocytoma crisis is a surgical emergency. However, retrospective study of a larger sample 
of patients presenting with pheochromocytoma crisis suggests that medical management 
in the acute setting is appropriate and safe. The ultimate treatment is indeed surgical; 
however, there is no clear recommendation for the acute management of pheochro‐
mocytoma crisis. This chapter will focus on the medical and surgical management of 
potentially life‐threatening pheochromocytoma crisis. An in‐depth review of the clinical 
presentation, pathophysiology, causes and treatments of pheochromocytoma crisis will 
be provided, including the controversial areas surrounding decision‐making and timing 
for adrenalectomy.
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1. Introduction
Pheochromocytomas are rare tumours of the sympathetic nervous system that arise from 
the chromaffin cells of the adrenal medulla. These tumours secrete catecholamines either 
intermittently or continuously. Pheochromocytomas are generally unilateral, in 90% of cases, 
whereas bilateral disease is found more commonly in the paediatric population and asso‐
ciated with genetic syndromes. Right‐sided adrenal tumours are more common and have 
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a higher preponderance to cause paroxysmal hypertension compared to left‐sided tumours 
that are generally associated with persistent hypertension. These tumours have an estimated 
incidence of 2–8 cases per million per year [1] and comprise less than 0.1% of the hyper‐
tensive population; however, approximately 90% of all patients with pheochromocytoma 
have associated hypertension [2]. Classic presentation of pheochromocytoma consists of a 
triad of symptoms, including headaches, diaphoresis and palpitations. The gold standard of 
treatment for pheochromocytoma is elective surgical resection after an appropriate, usually 
1–2 weeks, course of anti‐hypertensive therapy.
Pheochromocytoma multisystem crisis (PMC) was a term first described in 1988 [3]. This rare 
and potentially fatal entity consists of a tetrad of symptoms including haemodynamic instability 
and collapse, encephalopathy, hyperthermia and multi‐organ failure. PMC is not synonymous 
with hypertensive crisis; patients with PMC typically tend to have very labile blood pressures 
ranging from severe hypotension to severe hypertension (e.g. 60–250 mm Hg systolic). The 
treatment of PMC remains controversial, as there is no consensus among clinicians regarding 
the appropriate timing of adrenalectomy in the specific setting of pheochromocytoma crisis. 
This chapter will address the clinical presentation of PMC, pathophysiology of pheochromo‐
cytoma, causes of PMC and a description of medical versus surgical treatment. Finally, the evi‐
dence regarding emergency adrenalectomy to treat PMC compared with medical management 
will be discussed.
2. Clinical presentation
Pheochromocytoma has been termed the ‘great mimicker’ because it presents in a non‐ specific 
way that may be mistaken for other clinical entities. Patients presented with the classic triad 
of pheochromocytoma (i.e. headaches, palpitations and diaphoresis) may initially be given 
the misdiagnosis of migraine headaches or psychiatric conditions such as acute anxiety or 
panic attacks. This clinical situation can be particularly dangerous because some medications 
used for treatment (i.e. β‐blockers) may induce paroxysms of severe hypertension and subse‐
quent pheochromocytoma crisis. Some clinicians advocate that in cases with anxiety and/or 
migraines, such patients should undergo formal screening for pheochromocytoma because 
the treatment of the former conditions may precipitate a crisis [4].
PMC consists of a constellation of symptoms that can also resemble other life‐threatening 
conditions and can be difficult to diagnose if the patient is not already known for pheochro‐
mocytoma. PMC, which consists of haemodynamic instability with either severe hypotension 
or hypertension, labile hypertension, hyperthermia (≥40°C), encephalopathy and multi‐organ 
failure, can be confused with other diagnoses such as septic shock, thyroid storm and malig‐
nant hyperthermia. This complex can be deleterious to every organ system, resulting from 
excess norepinephrine secretion causing extreme vasoconstriction, but also due to vasodilata‐
tion from excess epinephrine secretion and volume contraction, with a subsequent low‐flow 
state. Encephalopathy may occur secondary to severe hypertension or direct effects of cat‐
echolamines on the brain. Other neurologic manifestations of PMC include cerebrovascular 
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accidents and seizures. Cardiac complications are numerous and may include cardiomyopathy, 
myocarditis, myocardial ischemia and necrosis secondary to coronary vasospasm, congestive 
heart failure, cardiac arrhythmias and cardiogenic shock. Pulmonary manifestations include 
pulmonary edema and acute respiratory distress syndrome. Patients with PMC may also pres‐
ent with acute liver failure, acute kidney injury, disseminated intravascular coagulation, lactic 
acidosis, diabetic ketoacidosis and rhabdomyolysis. Gastrointestinal manifestations include 
paralytic ileus and intestinal ischemia secondary to vasoconstriction. Vascular complications 
can include peripheral thrombosis, embolism and vasospasm [5, 6].
3. Pathophysiology
Pheochromocytomas arise from the chromaffin cells of the adrenal medulla. Chromaffin cells 
produce catecholamines, and pheochromocytomas can produce up to 27 times the synthetic 
capacity of the normal adrenal medulla. This high rate of production causes accumulation 
of catecholamines and their metabolites, metanephrines, in the cytoplasm of the chromaffin 
cells, which then diffuse out of the cells into the vascular system [2]. Tumour size directly cor‐
relates with levels of catecholamine secretion with smaller tumours secreting fewer hormones 
than larger tumours, whereas larger tumours reported to have wider variability of hormone 
secretion [7]. Most pheochromocytomas produce epinephrine and norepinephrine, which 
both act on G‐protein coupled adrenergic receptors [8].
Norepinephrine acts on α‐1‐adrenergic receptors that are located on smooth muscle cells 
within peripheral arteries and veins, causing vasoconstriction; α‐2‐adrenergic receptors, 
located on the presynaptic surface of sympathetic ganglia, cause coronary vasoconstriction 
and peripheral arterial dilatation; and β‐1‐adrenergic receptors located on cardiomyocytes, 
cause positive inotropic effects, as depicted in Figure 1. Activation of β‐1‐adrenergic recep‐
tors also causes increased secretion of renin, which increases the mean arterial pressure. 
Epinephrine primarily acts on β‐1‐ and β‐2‐adrenergic receptors. Activation of β‐2‐adrenergic 
receptors leads to vasodilatation of arteries as well as increased secretion of norepinephrine 
by the sympathetic ganglia.
Depending on the catecholamine secretory profile of the tumour, pheochromocytomas can 
have different clinical manifestations. Most pheochromocytomas secrete more norepineph‐
rine than epinephrine; however, they can secrete both hormones or secrete epinephrine alone. 
Severe hypertension may develop because of vasoconstriction from excess norepinephrine 
secretion whereas severe hypotension may result from widespread vasodilation caused by 
excess epinephrine secretion. Other mechanisms have been postulated to explain these changes 
in blood pressure. One of the explanations is that tumour necrosis may cause overwhelm‐
ing tumour cell death and an abrupt cessation of catecholamine secretion, thereby leading 
to severe hypotension. However, it has also been postulated that tumour cell death may lead 
to cell lysis and subsequent massive release of catecholamines and severe hypertension. It is 
unclear which pathophysiologic mechanisms are responsible for the haemodynamic instabil‐
ity associated with PMC, but each mechanism likely contributes to the overall clinical picture.
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4. Causes
Pheochromocytomas can cause sustained hypertension if there is continuous secretion of cat‐
echolamines, but can also cause paroxysmal hypertension with associated symptoms. If the 
paroxysm is severe, it may precipitate PMC, as reviewed in Table 1. PMC can occur sponta‐
neously, if there is necrosis or haemorrhage of the tumour itself or if there is any source of 
external pressure on the tumour. Changes in body position, for example, even something as 
benign as rolling over in bed, may induce PMC [2]. Vigorous exercise, especially if it involves 
bending and lifting, may also precipitate PMC, as well as any kind of trauma.
PMC may also occur in the perioperative period, in the setting of adrenalectomy or any other 
operative indication. PMC can be triggered by certain anaesthetic agents upon induction of 
general anaesthesia, upon incubation, bladder catheterization, surgical skin incision, estab‐
lishment of pneumoperitoneum and surgical manipulation of the tumour itself [9]. Anxiety 
and stress may also trigger an episode of PMC. Certain foods, such as aged cheeses, beer, 
wine, meats, fish, bananas and chocolate, especially those containing tyramine, have been 
reported to induce PMC [2].
Finally, many medications have been associated with PMC, including β‐blockers, glucocorti‐
coids, metoclopramide, various anaesthetic agents, tricyclic anti‐depressants, MAO  inhibitors, 
opiates, methyldopa, nicotine, cocaine and certain radio contrast media. The use of non‐ 
selective β‐blockers causes unopposed activation of α‐adrenergic receptors, thus exacerbating 
vasoconstriction and worsening hypertension. Glucocorticoid administration may cause PMC 
Norepinephrine
α−1
α−2
β−1
adrenergic
receptors
Epinephrine
β−1
β−2
adrenergic
receptors
Figure 1. Illustration of catecholamine‐receptor interaction.
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by stimulating catecholamine release from the tumour itself and also by potentiating the effects 
of catecholamines at the level of the endothelial and smooth muscle cells in the peripheral vas‐
culature [10]. Metoclopramide may cause PMC by stimulating catecholamine release by acting 
Spontaneous • Tumour necrosis
• Tumour haemorrhage
• Patient factors, e.g. anxiety, stress
Related to movement • Changes in body position, e.g. rolling over in bed
• Vigorous exercise
• Trauma
Periprocedural/perioperative • Induction of general anaesthesia
• Incubation
• Bladder catheterization
• Surgical skin incision
• Pneumoperitoneum
• Surgical manipulation of the tumour
Medications • β‐blockers
• Glucocorticoids
• Metoclopramide
• Anaesthetic agents: Intravenous, e.g. ketamine, atropine; inhalational, 
e.g. halothane, desflurane
• Paralytics: succinylcholine, pancuronium
• Antidepressants: Tricyclic agents, monoamine oxidase inhibitors
• Methyldopa
• Nicotine
• Cocaine
Food • Tyramine‐containing: Aged cheeses, wine
• Beer
• Meats
• Fish
• Bananas
• Chocolate
Special circumstance • Pregnancy: Normal foetal movements, compression of the tumour 
during labour, increased intra‐abdominal pressure during labour and 
delivery
Table 1. Causes of pheochromocytoma multisystem crisis.
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on serotonin type 4 receptors [11]. Any anaesthetic agent that induces catecholamine surges 
or histamine may precipitate PMC and may include: ketamine, which has sympathomimetic 
effects; succinylcholine, which can cause catecholamine surges and stimulation of autonomic 
ganglia, as well as possibly causing mechanical stimulation via muscle fasciculations in close 
proximity to the tumour; pancuronium, atropine and inhalational anaesthetics such as halo‐
thane, which is arrhythmogenic and desflurane, which is a sympathomimetic drug [9].
Special considerations should be made for pheochromocytoma in the context of pregnancy, 
as there may be adverse effects to both mother and foetus. PMC can be triggered by increased 
intra‐abdominal pressure during gestation and normal labour and delivery, normal foetal 
movements or tumour compression during labour. PMC almost inevitably occurs with vagi‐
nal delivery, and for this reason, pregnant patients with pheochromocytoma in the antepar‐
tum period should be delivered by Caesarean section. Depending on when the diagnosis of 
pheochromocytoma is made, the patient should undergo laparoscopic resection in the first 
or second trimester, or at time of Caesarean section after delivery. Unrecognized pheochro‐
mocytomas have been associated with very high incidences of morbidity and mortality, with 
reported values of 40% for maternal mortality and 56% for foetal mortality [2]. While maternal 
catecholamines do not cross the placenta, they can cause uteroplacental insufficiency and 
subsequent foetal demise [2].
5. Treatment options
Medical management of pheochromocytoma is necessary prior to surgical resection. For 
PMC, every attempt should be made to control labile blood pressure to reduce or stop the pro‐
gression of symptoms and thereby stabilize the patient. Many different classes of anti‐hyper‐
tensive agents can be used to treat hypertension in pheochromocytoma preoperatively before 
elective adrenalectomy. Intravenous agents such as phentolamine, a parenteral, short‐acting 
α‐adrenergic blocker; nitroprusside; nitroglycerin; nicardipine, a calcium‐channel blocker; 
atenolol or esmolol, β‐adrenergic blockers and magnesium sulphate have all been shown to 
effectively treat hypertensive crisis. Intravenous lidocaine is also used to treat cardiac arrhyth‐
mias seen in PMC.
The first‐line agents are α‐adrenergic blockers, the most common of which is phenoxyben‐
zamine, which is a non‐selective blocker with a long half‐life. Phenoxybenzamine decreases 
blood pressure, but may also increase the risk of tachycardia and decrease the risk of cardiac 
arrhythmias; this mechanism of action is achieved by blocking α‐adrenergic receptors and not 
by decreasing the synthesis of catecholamines. Selective α‐blockers are also used, including 
doxazosin and prazosin, which are as effective at treating haemodynamic instability as the 
non‐selective α‐blockers. These agents are associated with less reflex tachycardia and less 
post‐operative hypotension than non‐selective α‐blockers.
Calcium channel blockers (e.g. nifedipine, verapamil or diltiazem) are better tolerated by 
patients than α‐blockers; however, they are less effective therefore not usually a first‐line choice. 
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers have also been 
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used to control hypertension in pheochromocytoma, but not as first‐line agents and they usu‐
ally used in combination with other classes of medications to more effectively control blood 
pressure. Only β‐adrenergic blockers are typically administered after α‐blockers have been 
started, and they are used specifically to treat persistent tachycardia. Non‐selective β‐block‐
ers should not be used in the treatment of pheochromocytoma because of their effects on 
β‐2‐adrenergic receptors, which inhibit vasodilatation and worsen hypertension. Instead, 
selective β‐blockers should be prescribed at low doses as they act solely on β‐1‐adrenergic 
receptors, thereby decreasing heart rate. Alpha‐methyl‐para‐tyrosine can also be used to treat 
hypertension in pheochromocytoma, as it interrupts the first step in the biosynthesis of cat‐
echolamines by inhibiting the enzyme tyrosine hydroxylase. However, this drug has severe 
adverse effects that include psychiatric disturbances, extrapyramidal symptoms, sedation 
and urolithiasis, and its use, therefore, is generally reserved for patients with malignant or 
metastatic pheochromocytoma.
Surgical resection remains the definitive treatment for pheochromocytoma. Laparoscopic 
transperitoneal adrenalectomy is most commonly performed; however, other operations may 
be used, such as the lateral retroperitoneal, posterior retroperitoneal and transthoracic surgi‐
cal approaches. Successful adrenalectomy requires close communication between the surgical 
team and the anaesthesiology team, especially at the time of adrenal vein dissection and divi‐
sion, as the patient may develop profound hypotension once the vein is ligated. Tumour and 
adrenal gland manipulation should be minimized until after the vein is clipped. Timing of 
surgical resection in the context of PMC is very controversial, and there is no clear consensus 
among clinicians as to whether emergency adrenalectomy is indicated and/or is considered 
safe for PMC. The following section will review the literature pertaining to the treatment 
options, decision‐making and outcomes in PMC.
6. Initial management: when is it appropriate to operate?
The treatment of PMC has traditionally consisted of immediate medical stabilization followed 
by emergent or urgent adrenalectomy. There are three treatment options in the case of PMC, 
including: (1) emergent adrenalectomy, i.e. once the diagnosis of PMC is made, the patient 
proceeds directly to surgery; (2) urgent adrenalectomy, i.e. the patient’s haemodynamic sta‐
tus is first treated medically with a short course of α‐blockade prior to adrenalectomy, usually 
within 7–10 days of presentation and within the same hospital admission and (3) elective 
adrenalectomy, i.e. planned surgery following initial medical stabilization and discharge 
from hospital. The tendency for emergency adrenalectomy was based on anecdotal evidence 
from published case reports suggesting that medical management alone led to poorer out‐
comes. In 1980, one group recommended that only brief attempts should be made to stabilize 
the patient’s haemodynamic and that ‘procrastination’ prior to operative intervention would 
lead to ‘irreversible shock, renal failure and death’ [12]. In their series, two patients who 
presented with ‘acute pheochromocytoma’ both died, one in the post‐operative period and 
one in whom the diagnosis of pheochromocytoma had not been established. Another group 
 published a case series that included three cases of PMC [13]. One patient’s hypertensive  crisis 
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was successfully controlled prior to operative intervention, however, upon development of 
a fever of 40°C, a septic workup was initiated and the patient became encephalopathic, lead‐
ing to respiratory distress and had fatal cardiac arrhythmias while awaiting surgery. The 
second patient in their series presented with syncope and quickly developed multisystem 
organ failure despite adequate blood pressure control with multiple α‐ and ß‐blocking agents. 
Urgent adrenalectomy was eventually performed 4 days after hospital admission. The opera‐
tion was successful, but the patient’s post‐operative course was prolonged and she was left 
with long‐term sequelae of her encephalopathy, including quadriplegia and dysarthria. The 
third patient in the case series also presented with hypertensive crisis with rapid deteriora‐
tion to multisystem organ failure, and underwent emergency adrenalectomy on the seventh 
day following admission for refractory multi‐organ failure. Surgery was successful, and the 
patient’s multisystem crisis resolved post‐operatively.
More recently, several case reports have been published that also support urgent operative 
intervention in the setting of PMC. In 2008, a study described a case of PMC upon induction of 
general anaesthesia in the context of elective adrenalectomy for a known pheochromocytoma, 
despite preoperative α‐blockade [14]. Surgical resection was aborted, and the patient was 
transferred to the authors’ institution, where he remained in the intensive care unit for 6 days 
for aggressive medical stabilization followed by urgent adrenalectomy. The patient eventu‐
ally recovered from his multisystem organ failure and discharged from the hospital 1 month 
later. In 2010, a reported case of PMC was described that initially presented with acute respi‐
ratory failure and encephalopathy, in which surgical resection was performed 11 days after 
admission because of the patient’s progressive and uncontrollable medical deterioration [5]. 
Post‐operatively, the patient’s condition improved almost immediately, and the multisystem 
organ failure resolved except for chronic renal failure requiring long‐term haemodialysis. 
In another case report of a patient who presented with acute heart failure with cardiogenic 
shock refractory to inotropic pharmacotherapy, insertion of an intra‐aortic balloon pump was 
required, and extracorporeal membrane oxygenation (ECMO) was considered. The treating 
physicians, however, elected to proceed with emergent adrenalectomy. The patient’s haemo‐
dynamic and respiratory status greatly improved shortly after surgery [15].
Several other authors have challenged the notion that the only viable option for the treatment 
of PMC is emergency adrenalectomy. Elective adrenalectomy following intensive medical 
stabilization has been shown in several case reports. In a 12‐year‐old child, with severe dilated 
cardiomyopathy, secondary to excess catecholamine secretion from a pheochromocytoma 
was treated with anti‐hypertensives, specifically phenoxybenzamine and α‐methyl‐ para‐
tyrosine, for 7 months prior to surgical resection [16]. Cardiac function improved moder‐
ately with medical management alone in the preoperative period and normalized completely 
post‐ operatively. Another report described two cases of PMC resulting in respiratory failure 
requiring incubation and ventilation, and acute kidney injury requiring continuous venove‐
nous haemodialysis [4]. Adrenalectomy was performed at least 1 month after initial presenta‐
tion, following medical stabilization and maintenance.
The case reports above describe the clinical presentation of PMC in detail, but there is very 
limited data regarding the perioperative management of PMC and whether it is preferable to 
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proceed with emergency surgery with preoperative α‐blockade versus medical management 
alone in the immediate period of crisis, followed by hospital discharge and elective adrenal‐
ectomy. Current review of the literature only reports anecdotal evidence and consequently 
subject to publication bias. However, a recent retrospective chart review of PMC cases at 
their institution as well as a literature review of all cases of PMC that underwent adrenalec‐
tomy was performed [6]. The authors reviewed medical charts from March 1993 to October 
2011 of all patients who underwent adrenalectomy for a diagnosis of pheochromocytoma 
or paraganglionoma confirmed by pathology. They defined pheochromocytoma crisis as 
severe hypertension or hypotension resulting in end‐organ damage, and found that 25 of 137 
patients presented with crisis. None of the patients in their series underwent emergency sur‐
gery without initial α‐blockade. All but one patient was stabilized with phenoxybenzamine 
prior to adrenalectomy. Ten patients underwent urgent adrenalectomy during the same hos‐
pital admission, whereas the other 15 patients were discharged from hospital and returned 
for elective adrenalectomy. There were no mortalities in either group, but the major clini‐
cal significant difference was that there was an increased use of intra‐aortic balloon pumps, 
higher incidence of preoperative ICU admissions for crisis, higher post‐operative complica‐
tion rate, increased post‐operative ICU admissions and longer post‐operative length of stay 
in the urgent surgery group.
In their literature review, the authors found 97 patients who underwent adrenalectomy for 
PMC. In this group, they identified three different management options: emergency surgery 
without prior α‐blockade, urgent surgery with α‐blockade and medical stabilization and elec‐
tive surgery post‐discharge after medical therapy to initially treat the crisis. The combined data 
for patients undergoing elective and urgent surgery were compared to the emergency surgery 
group. The most striking significant difference between these groups was the mortality rate, 
which was found to be 18% in emergency surgery patients compared to 0% in the elective/
urgent surgery patients. There were other statistically significant differences, such as increased 
preoperative diagnosis of pheochromocytoma in the elective/urgent patients, higher incidence 
of tumour haemorrhage or rupture in the emergency surgery patients, higher incidence and 
longer duration of preoperative α‐blockade in the elective/urgent surgery patients, higher rate 
of laparoscopy in the elective/urgent surgery patients and increased risks of both intra‐opera‐
tive and post‐operative complications in the emergency surgery patients.
Currently, this is the only large‐scale study available regarding the management of pheochro‐
mocytoma crisis. Based on their experience from their own institutions, it appears feasible 
and safe to attempt medical therapy and elective adrenalectomy if the patient can be dis‐
charged safely from hospital, as outcomes are better for patients undergoing elective com‐
pared to urgent surgical resection during the same admission. From the data available in the 
literature, it is quite clear that emergency adrenalectomy without adequate preoperative α‐
blockade is associated with high morbidity and mortality in the treatment of PMC. It is there‐
fore recommended to offer urgent adrenalectomy in those patients who are able to partially 
recover under intensive medical management, while elective adrenalectomy can be reserved 
for patients who fully recover with medical management and who can safely be discharged 
from the hospital. Ideally, adrenalectomy should be planned within 4–6 weeks following dis‐
charge. This study is limited in that it is a retrospective review, but since PMC is such a rare 
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Figure 2. Decision‐making flow chart for patients presenting with PMC.
clinical entity, it would be very unlikely that a prospective, randomized study could ever be 
carried out [6]. Nevertheless, it seems clear that emergency adrenalectomy should be discour‐
aged as an initial treatment of PMC and that medical therapy and eventual urgent or elec‐
tive surgery should be the preferred management if the patient’s condition allows it. A flow 
diagram for decision‐making in patients with pheochromocytoma crisis is shown in Figure 2.
7. Conclusion
There has been a paradigm shift in the surgical management of PMC, from performing emer‐
gency adrenalectomy immediately after the diagnosis to now favouring medical stabilization 
followed by elective adrenalectomy in more controlled and ideal situation, but allowing for 
urgent adrenalectomy in the same hospital admission if necessary. There are currently no 
guidelines available or Level 1 evidence to support this change in practice, and randomized 
studies would be impractical to perform due to the rare presentation of this clinical entity. 
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Further retrospective studies with larger sample sizes may be helpful in discerning the clini‐
cal outcomes of different management strategies and making a stronger recommendation for 
the preferred treatment of PMC.
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